Literature DB >> 27514647

Hepatitis C virus prevention and treatment prioritization-ethical, economic and evidential dimensions of early rather than delayed treatment for people who inject drugs.

Matthew Hickman1, Natasha K Martin2, Richard Huxtable2.   

Abstract

Entities:  

Keywords:  Economic; HCV; ethics; injecting drug use; prevention; prioritisation; treatment

Mesh：

Year:  2016        PMID： 27514647      PMCID： PMC5233591          DOI： 10.1111/add.13521

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  15 in total

1.  Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.

Authors:  Norman Daniels; James Sabin
Journal:  Philos Public Aff       Date:  1997

Review 2.  Extent of illicit drug use and dependence, and their contribution to the global burden of disease.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

3.  EASL Recommendations on Treatment of Hepatitis C 2015.

Authors: 
Journal:  J Hepatol       Date:  2015-04-21       Impact factor: 25.083

4.  Hepatitis C reinfection after sustained virological response.

Authors:  Håvard Midgard; Benedikte Bjøro; Arild Mæland; Zbigniew Konopski; Hege Kileng; Jan K Damås; Jørn Paulsen; Lars Heggelund; Per K Sandvei; Jetmund O Ringstad; Lars N Karlsen; Kathrine Stene-Johansen; John H-O Pettersson; Dagny H Dorenberg; Olav Dalgard
Journal:  J Hepatol       Date:  2016-01-11       Impact factor: 25.083

5.  Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States.

Authors:  Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor
Journal:  Ann Intern Med       Date:  2015-08-04       Impact factor: 25.391

6.  Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.

Authors:  Andrew J Leidner; Harrell W Chesson; Fujie Xu; John W Ward; Philip R Spradling; Scott D Holmberg
Journal:  Hepatology       Date:  2015-03-16       Impact factor: 17.425

Review 7.  Enhancing our understanding of current therapies for hepatitis C virus (HCV).

Authors:  Neliswa A Gogela; Ming V Lin; Jessica L Wisocky; Raymond T Chung
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

8.  Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.

Authors:  Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; David J Goldberg; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

9.  Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).

Authors:  David R Walker; Marcos C Pedrosa; Shivaji R Manthena; Nikil Patel; Steven E Marx
Journal:  Adv Ther       Date:  2015-11-04       Impact factor: 3.845

10.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.

Authors:  Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman
Journal:  Hepatology       Date:  2013-08-26       Impact factor: 17.425
View more
  1 in total

1.  Knowledge of hepatitis C status moderates the relationship between history of drug treatment and sterile syringe use.

Authors:  Kiva Ariani Fisher; Laura Michele Cahill; Stephanie Broyles; Marion Rorke; William Thomas Robinson
Journal:  PLoS One       Date:  2018-04-27       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.